These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 36063818)

  • 1. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
    Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
    Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer: protocol for a multicentre, prospective, observational study.
    Shoji F; Yamashita T; Kinoshita F; Takamori S; Fujishita T; Toyozawa R; Ito K; Yamazaki K; Nakashima N; Okamoto T
    BMJ Open; 2022 Jun; 12(6):e061674. PubMed ID: 35676015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
    Ren S; Feng L; Liu H; Mao Y; Yu Z
    Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer.
    Nyein AF; Bari S; Hogue S; Zhao Y; Maller B; Sha S; Gomez MF; Rollison DE; Robinson LA
    BMC Cancer; 2022 Jan; 22(1):101. PubMed ID: 35073876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer.
    Duttagupta S; Hakozaki T; Routy B; Messaoudene M
    Curr Oncol; 2023 Oct; 30(11):9406-9427. PubMed ID: 37999101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer.
    Katayama Y; Yamada T; Shimamoto T; Iwasaku M; Kaneko Y; Uchino J; Takayama K
    Transl Lung Cancer Res; 2019 Dec; 8(6):847-853. PubMed ID: 32010563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy.
    Weis TM; Hough S; Reddy HG; Daignault-Newton S; Kalemkerian GP
    J Oncol Pharm Pract; 2020 Apr; 26(3):564-571. PubMed ID: 31238808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.
    Chau J; Yadav M; Liu B; Furqan M; Dai Q; Shahi S; Gupta A; Mercer KN; Eastman E; Hejleh TA; Chan C; Weiner GJ; Cherwin C; Lee STM; Zhong C; Mangalam A; Zhang J
    BMC Cancer; 2021 Jul; 21(1):808. PubMed ID: 34256732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
    Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
    Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment.
    Nucera F; Ruggeri P; Spagnolo CC; Santarpia M; Ieni A; Monaco F; Tuccari G; Pioggia G; Gangemi S
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating efficacy of "microbiota modulation of the gut-lung Axis" combined with chemotherapy in patients with advanced NSCLC: study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial.
    Xia Q; Chen G; Ren Y; Zheng T; Shen C; Li M; Chen X; Zhai H; Li Z; Xu J; Gu A; Jin M; Fan L
    BMC Cancer; 2021 Jun; 21(1):721. PubMed ID: 34157996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer.
    Ardizzoni A; Azevedo S; Rubio-Viqueira B; Rodríguez-Abreu D; Alatorre-Alexander J; Smit HJM; Yu J; Syrigos K; Trunzer K; Patel H; Tolson J; Cardona A; Perez-Moreno PD; Newsom-Davis T
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.
    Luo WC; Mei SQ; Huang ZJ; Chen ZH; Zhang YC; Yang MY; Liu JQ; Xu JY; Yang XR; Zhong RW; Tang LB; Yin LX; Deng Y; Peng YL; Lu C; Chen BL; Ke DX; Tu HY; Yang JJ; Xu CR; Wu YL; Zhou Q
    J Transl Med; 2024 Apr; 22(1):326. PubMed ID: 38566102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
    Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
    Thorac Cancer; 2020 Jun; 11(6):1621-1632. PubMed ID: 32329229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer.
    Shoji F; Yamaguchi M; Okamoto M; Takamori S; Yamazaki K; Okamoto T; Maehara Y
    Front Mol Biosci; 2022; 9():1040424. PubMed ID: 36353732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
    Thompson NA; Stewart GD; Welsh SJ; Doherty GJ; Robinson MJ; Neville BA; Vervier K; Harris SR; Adams DJ; Dalchau K; Bruce D; Demiris N; Lawley TD; Corrie PG
    BMC Cancer; 2022 Jan; 22(1):99. PubMed ID: 35073853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer.
    Hakozaki T; Richard C; Elkrief A; Hosomi Y; Benlaïfaoui M; Mimpen I; Terrisse S; Derosa L; Zitvogel L; Routy B; Okuma Y
    Cancer Immunol Res; 2020 Oct; 8(10):1243-1250. PubMed ID: 32847937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer.
    Boesch M; Baty F; Albrich WC; Flatz L; Rodriguez R; Rothschild SI; Joerger M; Früh M; Brutsche MH
    Oncoimmunology; 2021; 10(1):1988403. PubMed ID: 34912592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy.
    Sarkar J; Cortes Gomez E; Oba T; Chen H; Dy GK; Segal BH; Ernstoff MS; Ito F
    World J Oncol; 2023 Jun; 14(3):178-187. PubMed ID: 37350807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
    Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
    Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.